January 2, 2008 – Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients, under the age of 19, are rare, according to a study conducted by researchers at the University of Michigan Health Systems in Ann Arbor, MI,.
Studying 78,353 gadolinium-containing contrast injections over five years, acute allergic-like reactions occurred after 54 injections, 48 reactions involved adults and six occurred in pediatric patients. Seventy-four percent of these reactions were mild, 19 percent were moderate and seven percent were marked as severe.

December 28, 2007 - The data converter and amplifiers market for portable imaging systems will reach $582.7 million in 2011 up from $316 million in 2006, according to research from Frost & Sullivan.

December 27, 2007 - After a longer-than-expected maintenance shutdown, production of radioisotopes for molecular imaging and targeted therapy is back online at the National Research Universal (NRU) reactor in Chalk River, Ontario. The reactor was returned to service following direct intervention by the Canadian government, which in effect over-ruled the safety concerns of the Canadian Nuclear Safety Commission (CNSC).

December 27, 2007 - XTENT Inc. announced that it has submitted its application to the designated European Notified Body for CE Mark approval of its Custom NX DES System, while it continues U.S. pivotal trial discussions with the FDA.

XTENT’s CE Mark application includes the XTENT design dossier and the drug formulation submission from Biosensors International Group. XTENT plans to begin European sales of the Custom NX system in the second half of 2008 through partnerships with leading regional distributors, following CE Mark approval.

December 26, 2007 - Boston Scientific Corp. announced its TAXUS Liberte paclitaxel-eluting coronary stent system has received European CE Mark approval for use in patients with diabetes.